Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 in Advanced Solid Malignancies
NCT06281678Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC), sponsored by Innovent Biologics. Started Apr 2024; status: recruiting.
02
Drugs
IBI363
03
Conditions
melanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06281678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281678.